Long-term study of seralutinib for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a prior study of seralutinib for PAH.
- You must be willing to follow the study schedule and procedures.
- Women who could become pregnant must have a negative pregnancy test and use effective birth control during the study and for 30 days after.
- Men who are not sterilized and are sexually active with a woman who could become pregnant must use a condom during the study and for 90 days after.
- You should not have any serious medical condition that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
This trial is for adults with pulmonary arterial hypertension (PAH) who have been taking sotatercept for at least 6 months and have stable, low-risk disease. The study will check if it's safe to stop one of their other PAH treatments (a prostacyclin or selexipag).
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.